CORRESPONDENCE Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection Ital Nemet, Limor Kliker, Yaniv Lustig, et al N Engl J Med December 29, 2021DOI: 10.1056/NEJMc2119358 TO THE EDITOR: On November 26, 2021, the World Health Organization (WHO) named the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in South Africa, as a variant of concern.1 By November 29, 2021, thre...

Original Investigation January 25, 2022 Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 Matthew E. Oster, David K. Shay, John R. Su, et al JAMA. 2022;327(4):331-340. doi:10.1001/jama.2021.24110 Key Points Question  What is the risk of myocarditis after mRNA-based COVID-19 vaccination in the US? Findings  In this descriptive study of 1626 cases of myocarditis i...

ORIGINAL ARTICLE Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation Steffen Desch, Anne Freund, Ibrahim Akin, et al N Engl J Med 2021; 385:2544-2553DOI: 10.1056/NEJMoa2101909 Abstract BACKGROUND Myocardial infarction is a frequent cause of out-of-hospital cardiac arrest. However, the benefits of early coronary angiography and revascularization in resuscitated patients without electrocardiographic evidence of ST-segment elevatio...

ARTICLES|ONLINE FIRST Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial The ITAC (INSIGHT 013) Study Group Lancet Published: January 27, 2022 DOI:https://doi.org/10.1016/S0140-6736(22)00101-5 Summary Background Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG) to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, sp...

ARTICLES|ONLINE FIRST Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial Aurélien Mazeraud, Matthieu Jamme, Rossella Letizia Mancusi, et al Lancet Respir Med Published: November 11, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00440-9 Summary Background Acute respiratory distress syndrome (ARDS) is a major complic...

ARTICLES| VOLUME 399, ISSUE 10323, P437-446, JANUARY 29, 2022 Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study Nicole Wolter, Waasila Jassat, Sibongile Walaza, et al Lancet 2022; 399: 437-446 DOI: https://doi.org/10.1016/S0140-6736(22)00017-4 Summary Background The SARS-CoV-2 omicron variant of concern was identified in South Africa in November, 2021, and was associated with an incr...

ARTICLES|ONLINE FIRST Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study Jean-Pierre Gangneux, Eric Dannaoui, Arnaud Fekkar, et al Lancet Respir Med Published: November 26, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00442-2 Summary Background Patients with severe COVID-19 have emerged as a population at high risk of invasive fungal infections (IFIs). However, to our knowl...

ARTICLES|ONLINE FIRST Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial Zelalem Temesgen, Charles D Burger, Jason Baker, et al Lancet Respir Med Published: December 01, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00494-X Summary Background The pathophysiology of COVID-19 includes immune-mediated hyperinflammation, which could potentially lead to respiratory failure and death. Gra...

ARTICLES|ONLINE FIRST Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis Mary K Dahmer, Guangyu Yang, Min Zhang, et al Lancet Respir Med Published: December 06, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00382-9 Summary Background Previous latent class analysis of adults with acute respiratory distress syndrome (ARDS) identified two phenotypes, distinguished by the degree of inflam...

ORIGINAL ARTICLE Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients Robert L. Gottlieb, Carlos E. Vaca, Roger Paredes, et al N Engl J Med 2022; 386:305-315DOI: 10.1056/NEJMoa2116846 Abstract BACKGROUND Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with Covid-19 who are at high risk for...